Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank.

Zhu P. et al, (2020), Int J Obes (Lond)

Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report

LANDRAY M. et al, (2020), New England Journal of Medicine

Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.

Horby P. et al, (2020)

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

Horby P. et al, (2020)

Accelerometer-measured physical activity and functional behaviours among people on dialysis

Nawab K. et al, (2020), Clinical Kidney Journal

Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.

Lamprea-Montealegre JA. et al, (2019), Clin J Am Soc Nephrol

Kidney disease trials for the 21st century: innovations in design and conduct.

Herrington WG. et al, (2019), Nat Rev Nephrol

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Herrington WG. et al, (2018), Clin Kidney J, 11, 749 - 761

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.

Haynes R. et al, (2018), Circulation, 138, 1505 - 1514

Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.

3C Study Collaborative Group None., (2018), Am J Transplant, 18, 1424 - 1434

Confounding is not the only bias influencing associations of adiposity with cardiovascular disease.

Staplin N., (2018), Eur Heart J, 39, 1521 - 1522

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy.

Storey BC. et al, (2018), Kidney Int, 93, 1165 - 1174

Impact of CKD on Household Income.

Morton RL. et al, (2018), Kidney Int Rep, 3, 610 - 618

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.

Storey BC. et al, (2018), Kidney Int, 93, 1000 - 1007

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.

Mafham MM. et al, (2018), Nephrol Dial Transplant, 33, 257 - 264

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.

UK HARP-III Collaborative Group None., (2017), Nephrol Dial Transplant, 32, 2043 - 2051

Biliary Tract and Liver Complications in Polycystic Kidney Disease.

Judge PK. et al, (2017), J Am Soc Nephrol, 28, 2738 - 2748

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.

Reith C. et al, (2017), BMC Nephrol, 18

Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP).

Staplin N. et al, (2017), Clin J Am Soc Nephrol, 12, 546 - 552

Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.

Herrington W. et al, (2017), Hypertension, 69, 314 - 322

Load More

Include forthcoming?